Activity has plunged in the months since May, as the drumbeat of recession around the world became louder. Between the first and second halves of 2022, deal volume fell 40% to USD 1.364trn in 2H22 from USD 2.256trn in 1H22. The number of deals also shrank 33.5% to 14,369 over the same time frame, the least active second half since 2003.
Dealmakers are making smaller transactions, with deals in excess of USD 2bn declining at a much faster pace than overall M&A.
North America’s volume has contracted fastest as major stock indexes plunged into bear territory. The continent’s USD 1.59trn-worth of deals in 2022 is nearly half of 2021’s heady total, and 15% below the pre-pandemic average. North America’s global dominance has slipped too – from a 49% share of global M&A last year to 44% this year.
Despite an energy crisis brought by Russia’s invasion of Ukraine, Europe’s M&A has contracted less. The USD 1.03trn agreed in 2022 in the Old Continent is 30.7% lower than 2021, and 2.3% less than the pre-pandemic five-year average. The 12,198 transactions agreed in Europe are 13.7% lower than 2021 but 4.5% higher than the pre-pandemic average.
Seven of the year’s top 10 deals all took place in the first half of 2022. Microsoft’s [USD 75bn purchase of Activision Blizzard, announced in January is still the year’s biggest. Six happened in April and May alone, including VMWare’s USD 71.6bn sale to Broadcom [NASDAQ:AVGO]; India-based Housing Development Finance’s USD 60.8bn deal with HDFC Bank; Italy-based Atlantia’s USD 46.4bn sale to Blackstone and Elon Musk’s USD 41.3bn buyout of Twitter. The only top 10 deals to take place in 2H22 were Haleon’s USD 30.9bn demerger from GlaxoSmithKline in July, Horizon Therapeutics’USD 28.3bn purchase by Amgen in December, and Albertson’s USD 24.8bn acquisition by Kroger in October.
To brighter days…
Going forward, bankers say there is ample private-equity dry powder and cash on corporate balance sheets for dealmaking to rebound in 2023. Many deals have stalled because of a persistent valuation gap, although that is closing. Given weakened valuations, many companies are opting to sell a stake instead of the whole thing.
Potential deals in the US in 2023 could include food additives business Innophos, which is running a sales process, according to Mergermarket. In Europe, UK veterinary group VetPartners and Italian family-owned pharmaceutical company Alfasigma are preparing for 2023 sales, according to Mergermarket. In Asia Pacific, Norway’s Telenor is looking to divest its USD 1bn Pakistan business, while KKR may opt to sell a stake in pub operator Australian Venue Co after considering a full exit.